Krystal Biotech (KRYS) has drawn fresh attention after recent trading left the stock with a 1 day return of 3.35% and a past 3 months return of 48.25%, prompting investors to reassess its profile.

That move comes on top of a 13.3% 7 day share price return, an 18.2% 30 day share price return, and a 48.3% 90 day share price return. The 1 year total shareholder return of 94.7% and 3 year total shareholder return above 2.5x suggest strong momentum has built over time.

If Krystal Biotech's run has caught your eye, this could be a good moment to broaden your watchlist with healthcare stocks that are also attracting attention.

With Krystal Biotech trading around $282.01, near recent price targets but with an intrinsic value estimate that implies a sizeable discount, the key question is whether markets already reflect its genetic medicine pipeline or whether there is still an opportunity for investors who believe the current price does not fully incorporate potential future growth.

Most Popular Narrative: 26.5% Overvalued

Compared with the last close at $282.01, the most followed narrative points to a fair value of about $223, suggesting the current price sits well above that estimate while still reflecting a robust growth story built around Krystal Biotech's genetic medicine platform.

The analysts have a consensus price target of $205.2 for Krystal Biotech based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $252.0, and the most bearish reporting a price target of just $166.0.

Curious what kind of revenue curve and margin profile could still justify a premium to that fair value line, even with a lower future P/E baked in? The narrative leans heavily on sustained high growth and profitability to bridge the gap between modelled earnings power and today’s share price expectations. If you want to see exactly how those earnings and revenue paths are stitched together, the full story lays out the assumptions in black and white.

Result: Fair Value of $223 (OVERVALUED)

However, the story can change quickly if Vyjuvek growth cools, or if reimbursement and pricing push those high 90% gross margins and projected net margins under pressure.

Another View: SWS DCF Points To A Large Gap

While the popular narrative tags Krystal Biotech as about 26.5% overvalued versus a fair value of $223, our DCF model points in the opposite direction. With an estimated fair value of $555.39, the current $282.01 price screens as trading at a large discount. Which story do you think fits your own expectations?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Krystal Biotech for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 867 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own Krystal Biotech Narrative

If you look at these numbers and reach a different conclusion, or simply prefer to test your own assumptions, you can build a personalized view in just a few minutes with Do it your way.

A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Krystal Biotech.

Looking for more investment ideas?

If Krystal Biotech has you thinking about what else might belong on your radar, do not stop here. Let the data guide you toward your next step.

• Spot potential value gaps by checking out these 867 undervalued stocks based on cash flows that may be trading below what their cash flows imply.
• Explore major tech shifts by scanning these 24 AI penny stocks that connect artificial intelligence themes with listed companies.
• Add income ideas to your watchlist by reviewing these 12 dividend stocks with yields > 3% that could support a yield focused approach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.